This study describes a novel, neutralizing monoclonal antibody (mAb), 11D7, discovered by
mouse immunization and hybridoma generation, against the parental Wuhan‐Hu‐1 RBD of …

The appearance of several coronavirus pandemics/epidemics during the last two decades
(SARS-CoV-1 in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019) indicates that …

The management of coronavirus disease 2019 has become more complex due to the
expansion of available therapies. The presence of severe acute respiratory syndrome …

Nanobodies are natural anti-SARS-CoV-2 drug candidates. Engineering multivalent
nanobodies is an effective way to improve the functional binding affinity of natural …

Background To date, most countries lifted the restriction requirement and coexisted with
SARS-CoV-2. Thus, dietary behavior for preventing SARS-CoV-2 infection becomes an …

Anti-Spike monoclonal antibodies have been considered a promising approach to COVID-
19 therapy. Unfortunately, the advent of resistant lineages jeopardized their effectiveness …

The COVID-19 pandemic saw unprecedented resources and funds driven into research for
the development, and subsequent rapid distribution, of vaccines, diagnostics and directly …

Most individuals infected with or vaccinated against COVID-19 develop antigenic
neutralizing immunoglobulin G (IgG) antibodies against the SARS-CoV-2 spike protein …

This study evaluated the efficacy and safety of neutralizing monoclonal antibodies (mAbs)
with usual care in patients with coronavirus disease 2019 (COVID-19). Randomized …

Relative alchemical binding free energy calculations are routinely used in drug discovery
projects to optimize the affinity of small molecules for their drug targets. Alchemical methods …